DALLAS, Jan. 30, 2014 /PRNewswire-iReach/ -- ReportsnReports.com adds "Pharmaceutical Business Confidence Report Q1 2014" & "Pharmaceutical Business Confidence Report Q4 2013" reports to its research database.
"Pharmaceutical Business Confidence Report Q1 2014" is a new report by Kable that analyzes the pharmaceutical industry executives' views on the global economy, expectations on customer confidence, supplier prices, key business concerns, and how executives' future investments are set to change in Q1 2014. This report also gives you access to regional analysis of industry outlook, industry and company growth prospects, future opportunities, staff hiring, and sales performance. Apart from providing access to the opinions and strategies of global pharmaceutical industry executives, it also examines their actions surrounding business priorities, threats and opportunities, and future investment areas over the next six months. Moreover, this report provides a comparative analysis of survey results with Q4 2013 wherever applicable. Get a copy of the complete report @ http://www.reportsnreports.com/reports/274168-pharmaceutical-business-confidence-report-q1-2014.html.
This report is the result of an extensive survey drawn from this research exclusive panel of leading global pharmaceutical industry executives. The report analyzes current economic conditions prevailing across the globe and their impact on the pharmaceutical industry, and forecasts, company and industry growth prospects over the next six months. Furthermore, it provides information about the impact of customer confidence, supplier prices, and staff headcount likely to affect the investment decisions of the industry over the next six months. Additionally, this report tracks the change in executives' perceptions during the last three months, by providing a comparative analysis of survey results with the previous quarter.
What is the current market landscape and what is changing?
Overall, 74% and 60% of global pharmaceutical industry executives are optimistic about the future growth prospects of both their company and the industry, respectively, over the next six months. Optimism towards the company and industry growth prospects has improved by eight and ten percentage points, respectively, in Q1 2014, compared to Q4 2013 results.
What are the key drivers behind recent market changes?
Optimism towards industry and company growth is driven by the improving global economic conditions, investments in emerging markets, and the introduction of new products in the market.
What makes this report unique and essential to read?
"Pharmaceutical Business Confidence Report Q1 2014" is a new report by Kable that analyzes the industry sentiments globally on the latest economic and customer issues and their impact upon investment decisions and growth prospects within the pharmaceutical industry. This report also examines the executive opinion about the current and future state of the economy and its retrospective effect on the industry. Furthermore, it analyzes the likely effect of supplier price changes, sales performance, and staff headcount within the industry over the next six months. In addition, it provides an overview of the key priorities, threats, and opportunities for the global pharmaceutical industry over the next six months. Furthermore, it also tracks the change in the industry executives' thought process, by providing a comparative analysis of survey results with Q4 2013, wherever applicable. Place a direct purchase order @ http://www.reportsnreports.com/Purchase.aspx?name=274168.
- Of respondents, 66% anticipate a positive change in the global economic outlook over the next six months. In comparison to previous quarter, the percentage of respondents who expect a positive change has increased by eighteen percentage points.
- Pharmaceutical industry executives plan to increase investments in the areas of new product development and marketing in the next six months.
- Executives operating in the Rest of the World and Asia-pacific anticipate the highest average sales increase of 6.4% and 4.5%, respectively, over the next six months.
- Industry executives operating in the Rest of the World and Europe anticipate an average increase of 3.2% and 2.2%, respectively, in their current workforce.
- Executives operating across the globe consider 'increasing sales', 'improving operational efficiency', and 'customer retention' as key priorities over the next six months.
Pharmaceutical Business Confidence Report Q4 2013 views on the global economy, expectations on consumer confidence, supplier prices, key business concerns, and how executives' future investments are set to change in Q4 2013.
Research and Investment Value Analysis of China Chemical Pharmaceutical Industry, 2013-2017: The chemical pharmaceutical industry has kept a high level and steady growth rate for recent 6 years, sales revenue of 2011 reaching CNY 715.516 billion and 23.40% growth rate, which is mainly influenced by the good economical development of China, rigid demand of an aging population, the introduction of a series of medical reform policy including increase in the proportion of health insurance reimbursement etc.
Research and Development Forecast of China Pharmaceutical Chain Market, 2013-2017 Firstly the report makes the overview of China pharmaceutical circulation industry's development, makes the introduction and analysis of the industry's management system and related policies and further points out the future investment opportunities
ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, consumer goods, environment, medical devices, healthcare, food and beverages, retail, water, advanced materials and much more.
Media Contact: Priyank Tiwari, ReportsnReports, +1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com